Share on StockTwits

XenoPort (NASDAQ:XNPT) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Friday, reports. They currently have a $7.20 target price on the stock. Zacks‘ price objective suggests a potential upside of 14.47% from the stock’s previous close.

XenoPort (NASDAQ:XNPT) traded down 4.45% during mid-day trading on Friday, hitting $6.01. 6,004,215 shares of the company’s stock traded hands. XenoPort has a 52 week low of $4.24 and a 52 week high of $9.11. The stock’s 50-day moving average is $5.79 and its 200-day moving average is $5.44. The company’s market cap is $286.9 million.

XenoPort (NASDAQ:XNPT) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.39) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.51) by $0.12. The company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.03 million. During the same quarter last year, the company posted ($0.41) earnings per share. XenoPort’s revenue was up 530.0% compared to the same quarter last year. Analysts expect that XenoPort will post $-1.87 EPS for the current fiscal year.

XenoPort, Inc is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders.

To view Zacks’ full report, visit

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.